Clinical advances in systemic lupus erythematosus

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate exciting advances for individuals suffering from systemic lupus erythematosus (SLE). The first is a phase II clinical study of a promising oral treatment, baricitinib. The second demonstrates the effective use of shingles vaccine in SLE patients who are particularly prone to this infection.

Go to Source

(Visited 6 times, 1 visits today)

Site Footer

Sliding Sidebar